Pharma Reviews: New Year, new requirements- Cos stare at high compliance costs with new laws

“Indian pharma companies are taking regulatory risks emanating from US FDA, US Foreign Corrupt Practices Act and Indian government's Uniform ...
Read more: New Year, new requirements- Cos stare at high compliance costs with new laws